Thirty Years of Pancreas Transplantation at Leiden University Medical Center: Long-term Follow-up in a Large Eurotransplant Center by Kopp, W.H. et al.
Thirty Years of Pancreas Transplantation at
Leiden University Medical Center: Long-Term
Follow-Up in a Large Eurotransplant Center
Wouter H. Kopp,1 Merel J.J. Verhagen,1 Joris J. Blok,1 Volkert A.L. Huurman,1 Johan W. de Fijter,2
Eelco J. de Koning,2 Hein Putter,3 Andzrej G. Baranski,1 Alexander F.M. Schaapherder,1 Andries E. Braat,1
and Jan Ringers1
Background.An overview of 30 years of pancreas transplantation at a high volume center. Analysis of patient survival– and
graft survival–associated risk factors. Methods. All pancreas transplantations performed in our center from January 1,
1984, till December 31, 2012, were evaluated. Covariates influencing pancreas graft survival were analyzed using both univariate
and multivariate analysis and Kaplan-Meier analysis. Results. In the study period, 349 pancreas transplantations were per-
formed. With the introduction of modern induction therapy in 1999, 5-year patient survival improved to 92.0% (P = 0.003).
Five-year pancreas graft survival improved to 80.3% (P = 0.026). Pancreas graft survival was influenced by left or right donor
kidney, transplant type, local origin of procurement team, pancreas cold ischemia time, recipient cerebrovascular disease.
Pancreas donor risk index increased to 1.39 over the years and pancreas donor risk index 1.24 or higher is a risk factor for graft
survival (P = 0.007). Conclusions. This study has shown excellent results in patient and pancreas graft survivals after
30 years of pancreas transplantation in a high volume center. Different donor, transplant, and recipient related risk factors
influence pancreas graft survival. Even with higher risk pancreas donors, good results can be achieved.
(Transplantation 2015;00: 00–00)
S imultaneous pancreas and kidney (SPK) transplantationis currently the first choice of treatment for patients with
type 1 diabetes mellitus (T1DM) and related end-stage renal
disease. Pancreas transplant alone (PTA) transplantation can
be performed in case of T1DMwith preserved kidney function
in case of hypoglycemic unawareness.1
The first pancreas transplantation in the Netherlands was
performed at the Leiden University Medical Center (LUMC)
in 1984.2 Over the past 30 years, LUMC has become one
of the largest pancreas transplantation centers within the
Eurotransplant region.3
In the current literature, there are several publications re-
porting on long-term results after pancreas transplantation.
The first large series were described by Sutherland et al4
in 2001. More recently, Sollinger et al5 also reported on
22 years of follow-up of 1000 pancreas transplantations in
Wisconsin, followed by more recent reports describing risk
factors and long-term experiences.6-9 The largest European se-
ries is from Innsbruck, Austria, reporting on results of 509 con-
secutive pancreas transplantations with long-term follow-up.10
However, when comparing results from different trans-
plant centers, it appears that no standard definition of pancreas
graft survival is being used,making adequate comparison dif-
ficult. In 2008, the Pancreas Transplant Committee (PTC) of
the Organ Procurement Transplantation Network (OPTN)
pled for 1 definition of pancreas graft function and failure,
pointing out the importance of a unified definition, which
should be used worldwide.11
In most studies, several donor-, transplant-, and recipient-
related risk factors are believed to influence outcome after
transplantation. The pancreas donor risk index (PDRI) was
constructed by Axelrod and allowed for structural assessment
of donor quality and prediction of 1 year graft survival after
pancreas transplantation.8
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Furthermore, center volume may also play a role in the
outcome. In 2004, Mandal has shown that low volume pan-
creas transplantation centers (<10 transplantation/year) have
poorer outcome in graft survival compared to medium
(10–20 transplantations/year) or high (>21 transplantations/
year) volume centers.12
The objective of this study is to describe the results, mea-
sured in patient and pancreas graft survivals, of 30 years
of pancreas transplantation in recipients with T1DM and
possible related complications at the LUMC and to analyze
donor-, transplant-, and recipient-related risk factors influenc-
ing pancreas graft survival. Also, we hope to show that with
relatively lower quality donors, indicated by high PDRI, we
are able to achieve good outcome in our high volume center.
METHODS
This study is a retrospective database analysis of all con-
secutive pancreas transplantations performed at the LUMC,
from the first pancreas transplantation onMay 14, 1984, till
December 31, 2012. For all 349 transplantations, follow-up
was collected until October 31, 2013.
Data Collection
All donor, transplant (Table 1), and recipient (Table 2)
characteristics were systematically registered. Follow-up data
were recorded to analyze outcome after pancreas transplan-
tation, including; Hba1c levels, insulin use, c-peptide, fasting
plasma glucose, patient death date and cause, failure date,
failure cause, number of treated rejection episodes, date of
transplantectomy, date last patient contact.
Postoperative Care
From March 1999, patients received any form of modern
induction therapy, either interleukin (IL)-II receptor antago-
nist or antithymocyte globulin (ATG). Currently, first started
in December 2007, induction therapy consists of adminis-
tration of anti-CD52 monoclonal antibody (alemtuzumab).
Before 1999, patients received either anti-CD3 antibody
(OKT3) or no induction therapy. As maintenance therapy,
recipients are currently administered combination therapy,
consisting of tacrolimus and mycophenolate mofetil. Until
1996, recipients received cyclosporine, azathioprine, and pre-
dnisone. From that time, until 2002, when cyclosporine was
replaced with tacrolimus, patients received mycophenolate
mofetil instead of azathioprine. Starting in 2008, routine ad-
ministration of prednisone was ceased. Patients currently
TABLE 1.
Donor and transplant factors and their influence in univariate
analyses on pancreas graft survival
Donor Factor N (%) Pa χ2













Diabetes mellitus 0 (0) n/a
Hypertension (yes) 26 (7) 0.11 2.559
Malignancy (yes) 1 (0.3) 0.589 0.292
Drug use (yes) 8 (2) 0.51 0.426
Alcohol use (yes) 7 (2) 0.08 2.984
HCVAb pos 0 (0) n/a
HBcAb pos 2 (1) 0.342 2.143
HIVAb pos 0 (0) n/a
CMV IgM/IgG pos 130 (37) 0.76 0.092
Cardiac arrest (yes)b 40 (12) 0.019 5.508
Hypotensive period (yes)c 123 (35) 0.56 0.342
Use of vasopressors (yes) 277 (79) 0.52 0.405
DCDD (yes) 6 (2) 0.86 0.031
Median (range) Pd
Age, y 36 (10‐57) 0.006
BMI 23 (14‐35) 0.81
Serum sodium, mmol/L 144 (123‐175) 0.58
Serum creatinine, μmol/L 70 (25‐190) 0.3
Serum lipase, U/L 20 (7‐332) 0.61
Serum amylase, U/L 80 (7‐1756) 0.029
ICU stay, d 2 (1‐33) 0.058













Donor kidney <0.001 32.951
No kidney 24 (7)
Leftb 276 (79)
Right 49 (14)





Transplant Factor N (%) Pa χ2
Median (range) Pd
Cold ischemia time, h 12 (3‐20) 0.005
PDRI 1.24 (0.68‐2.31) 0.25
P-PASS 16 (9‐22) 0.74
a Univariate Kaplan-Meier analysis (log rank Mantel-Cox).
b Favorable factor in univariate analysis.
c Defined as: systolic pressure <80 mm Hg, for at least 10 minutes.
d Univariate Cox-regression analysis.
n/a, not applicable; HTK, histidine-tryptophan-ketoglutarate; ICU, intensive care unit; IgG, immunoglob-
ulin G; IgM, immunoglobulin M.
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receive low dose (2850 IE) lowmolecular weight heparin in a
twice-daily regime as graft thrombosis prophylaxis. This re-
gimewas started in 2008. Before that, regular antithrombotic
therapy consisted of the same dose, administered once daily.
On discovery of partial graft thrombosis, patients are pre-
scribed vitamin K antagonist for a duration of at least
3 months. Routine computed tomography imaging is per-
formed between the 4th and 7th day after transplantation,
depending on renal (graft) function.
Analysis
Outcome was characterized by patient survival and graft
survival. Patient death with a functioning graft was not con-
sidered as graft failure (death-censored graft survival).
The moment of pancreas graft failure was determined
using the “uniform definition of graft function/failure for
whole pancreas and islet transplant” by the OPTN PTC as a
guideline11 (see Table S1, SDC, http://links.lww.com/TP/B112).
Endocrine pancreatic function was subdivided in grades A
to E, using HbA1c and use of insulin as markers for pan-
creatic graft function. In this study and in particular, when
performing univariate analysis, the OPTN definition of graft
failure was used as a guideline, in which allograft function
classified as grade A and B were considered as functioning
grafts, and grafts with grades C, D, and E were considered
as failed allografts. According to this definition, persistent
HbA1c greater than 6.3% and/or insulin was classified as
grade C (insulin use less than 50% of pretransplant dose)
or grade D (insulin use more than 50% of pretransplant
dose), and persistant HbA1c 7.0% or higher was classified
as grade E. Standard OGTTwas not performed in analyzing
graft function, for this was not required for classification of
graft failure using the OPTN PTC definition. Graft throm-
bosis was defined as the presence of intravascular thrombus,
proven after removal of the pancreas graft in case of complete
thrombosis and, in case of partial thrombosis, presence of
partial intravascular thrombus. Technical failure (TF) con-
sists of pancreas graft thrombosis, infections, graft pan-
creatitis, leakage, and bleeding.13 Early graft failure was
defined as graft failure within 90 days after transplantation.7
To compare groups based on outcome, we used the start of
modern immunosuppressive induction therapy (ATG/IL-II
receptor antagonist/alemtuzumab) in March 1999 as a
dividing point in the analysis of graft survival. The start of
immunosuppressive therapy as induction therapywas a land-
mark in transplantation medicine, with marked improve-
ment of long-term results in pancreas transplantation.
Statistical Analysis
For statistical survival analysis, Kaplan-Meier and Cox
regression models were performed using SPSS version 20.0.
Significant factors in univariate analysis will be entered into
amultivariate model. Other factors will be added to themodel
using stepwise forward selection. A P value less than 0.05
was considered significant for factors in both univariate and
multivariate analyses.
RESULTS
Donor and transplant characteristics are shown in Table 1.
In the study period, a total of 349 consecutive pancreas trans-
plantations were performed at the LUMC, of which 325
(93.1%) were simultaneous pancreas kidney, 21 (6.0%)
were pancreas after kidney, and 3 (0.9%) were PTA. Mean
follow-up was 8.0 years (0–24.2 years). Recipient charac-
teristics are shown in Table 2. Primary indication for trans-
plantation was T1DM (99.7%) with (96.8%) or without
(2.9%) renal complications. In total, 19 retransplantations
(5.4%) were performed, all were included in the analysis.
In univariate analysis, death-censored pancreas graft
survival was influenced by the following donor- and
transplantation-related risk factors: donor age (P = 0.006),
donor alcohol use (P = 0.08), serum amylase (P = 0.029),
origin of procurement team (P < 0.001), transplantation
type (P < 0.001), donor kidney side (P < 0.001), perfusion
fluid (P < 0.001), and cold ischemia time (P = 0.005). Donor
TABLE 2.
Recipient factors and their influence in univariate analyses on
pancreas graft survival
Recipient Factor N (%) Pa χ2








Type of dialysis 0.835 0.361
No dialysis (preemptive transplant) 144 (41)
Haemodialysis 93 (27)
Peritoneal dialysis 112 (32)
Repeated transplantation 0.4 0.715
First transplant 330 (95)
Retransplant 19 (5)
Thromboembolic event 4 (1) 0.253 1.307
Cerebrovascular disease 21 (6) 0.011 6.418
Coronary artery disease 54 (16) 0.591 0.289
Coronary artery bypass grafting 11 (3) 0.557 0.345
Percutaneous transluminal
coronary angioplasty
23 (7) 0.382 0.763
Cytomegalovirus mismatch 0.121 2.41
No mismatch (D−/R−) 269 (77)
D+/R− 72 (21)
Unknown 8 (2)
Modern induction therapy 0.026 4.939
Yesb 237 (68)
No 112 (32)





Age 42 (23‐64) 0.99
BMI 24 (17‐33) 0.2
Time on waiting list 1.1 (0‐10) 0.32
Time since DM I, y 27 (12‐48) 0.51
Time since first dialysis treatment, y 0.69 (0‐8) 0.3
Total HLA mismatches 4 (0‐6) 0.86
a Univariate Kaplan-Meier analysis (log rank Mantel-Cox).
b Favorable factor in univariate analysis.
c Univariate Cox-regression analysis.
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cardiac arrest had a protective effect on pancreas graft sur-
vival (P = 0.019), not on kidney graft survival (P = 0.823).
Retransplantation was found not to be a significant co-
variate for pancreas graft survival in univariate analysis
(P = 0.40). Recipient-related risk factors influencing pan-
creas graft survival were: cerebrovascular disease (P = 0.011)
and induction therapy (P = 0.026). Results of the univariate
analyses of death-censored OPTN-defined graft survival of
all donor, transplant, and recipient factors are also reported
in Tables 1 and 2.
In 256 (73%) patients, bladder drainage was initial drain-
age method. Of these patients, 171 (66.7%) were converted
to enteric drainage. Median (25th–75th percentile) inter-
val between transplantation and conversion was 339
(173–772) days. Recipients who were bladder drained and
not converted to bowel drainage had significantly worse
pancreas graft survival (P < 0.001)
Overall patient survival at 1, 5, and 10 years was 95.7%,
86.9%, and 74.6%, respectively. One-, 5-, and 10-year
overall pancreas graft survival was: 83.6%, 76.4%, and
70.8%, respectively, using the OPTN definition. Death-
censored pancreas graft survival was 85.1%, 78.2%, and
72.8% at 1, 5 and 10 years in the SPK subgroup. For pan-
creas after kidney, this was 66.0% and 55.0%, longest
follow-up before pancreas graft failure was 8.9 years. Lon-
gest death-censored graft survival was 3.2 years for PTA
grafts, with 1 year graft survival at 33.0%.
When pancreas graft failure occurred (n = 99), in the
majority of cases, this was caused by graft thrombosis
(35.4%) or rejection (20.2%). Other causes of graft failure
were atrophy or exhaustion of the graft (6.1%), infection
(5.1%), and bleeding (4.0%). Early pancreas graft failure
due to TF occurred in 33 cases, 29 of which were due to
graft thrombosis. From January 1, 2001, 43 cases of par-
tial graft thrombosis occurred in 213 patients (20.2%).
From January 1, 2008, the incidence of graft failure due to
complete thrombosis was 9.3%.
Kidney graft survival at 1, 5, and 10 years was 91.6%,
87.9%, and 81.6%. Kidney graft survival was significantly
better when left kidneywas donated, compared towhen right
kidney was donated: 94.4% versus 75.7% at 1 year follow-up
(P < 0.001). Main reasons for right kidney graft loss were
rejection (33.3%) or patient death (33.3%). Right kidney
graft loss due to thrombosis occurred in 1 case.
Clinical Outcome in Different Periods of
Induction Therapy
Long-term results of the transplantations performed in the
LUMC are shown in Figure 1, divided by transplant period
(using the start of modern induction therapy in March 1999
as a dividing point). Two hundred thirty-seven (67.9%) re-
cipients received modern induction therapy. Recipients in the
induction therapy group were older (P < 0.001), had higher
body mass index (P = 0.004), had been on the waiting list
longer (P < 0.001), and had longer duration of diabetes
mellitus (P < 0.001). They received pancreas grafts from
higher body mass index donors (P = 0.025) and higher
Pancreas-Preprocurement Allocation Suitability Score do-
nors (P < 0.001). Donors also had higher creatinine levels
(P = 0.013), had had less hypotensive periods (P = 0.003),
but had had more cardiac arrests (P = 0.001). They received
more regionally allocated grafts (P = 0.001), but less local
and extraregional allocated grafts (P = 0.001) Also, they re-
ceived more grafts procured by the local team (P < 0.001). In
the modern era, more pancreas grafts were transplanted with-
out kidney, but less with right kidney (P < 0.001). Addition-
ally, 20 (8.4%) were PAK in the modern era versus 1 (0.9%)
in the historic group (P = 0.022). All recipients in the historic
group were bladder drained, whereas 91 (38.4%) in the
modern group were primarily enteric drained (P < 0.001).
Patient survival (Figure 1A) at 1-year, 5-year, and 10-year
follow-up was, respectively, 93.8%, 78.4%, and 65.7% for
the historic group and 96.6%, 92.0%, and 80.9% for mod-
ern induction therapy group and was significantly better in
the more recent period (P = 0.003). Death-censored pancreas
graft survival (Figure 1B) at 1, 5, and 10 years was 73.0%,
68.2%, and 65.0%, respectively, in the historic group, and
88.5%, 80.3%, and 72.3%, respectively, in the modern in-
duction therapy group. These results were also significantly
better in the modern era (P = 0.026).
FIGURE 1. A, Kaplan-Meier survival curves of patient survival di-
vided by use of induction therapy (P = 0.003). B, Kaplan-Meier sur-
vival curves of OPTN-defined death censored graft survival divided
by use of induction therapy (P = 0.026).
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Different regimes of induction therapy led to following
1-year, 5-year, and 10-year pancreas graft survival rates: 75.6%,
69.5%, and 66.8% without induction therapy; 68.0%,
64.0%, and 64.0% for OKT3; 89.1%, 83.5%, and 77.4%
for IL-II receptor antagonists; 85.1%, 78.2%, and 67.1%
for ATG; and 91.2% for alemtuzumab. Long-term follow-up
(5 years and 10 years) of alemtuzumab induction therapy is
not yet available.
In the first 6 months after transplantation, kidney biopsy-
proven acute rejection in SPK transplantation recipients occurred
in 85.9% of recipients without induction therapy (n = 91),
82.6% with OKT3 (n = 25), 52.8% with IL-II receptor
antagonists (n = 37), 42.6% with ATG (n = 108), and
11.4% with alemtuzumab (n = 81) (P < 0.001). Data on
induction therapy were missing for 6 patients; 1 patient
received both IL-II receptor antagonist and ATG.
Multivariate Analysis
Stratified by induction therapy, in a multivariate Cox-
regression analysis, significant factors from univariate
analysis were entered. Other factors were entered, and the
model was fitted using forward selection. Significant fac-
tors of this multivariate analysis were: donor left versus
right kidney: hazards ratio (HR), 3.18 (95% confidence
interval [95% CI], 1.49–6.76, P = 0.003); SPK versus
PAK/PTA: HR, 3.68 (95% CI, 1.65–8.19; P = 0.001);
local origin of procurement center: HR, 2.72 (95% CI,
1.11–6.68, P = 0.029); pancreas cold ischemia time: HR,
0.9 (95% CI, 0.81–0.99; P = 0.033); recipient cerebrovas-
cular disease: HR, 3.52 (1.41–8.78, P = 0.002) for OPTN-
defined death-censored pancreas graft survival (Table 3).
Primary enteric or bladder drainage was borderline associ-
ated with pancreas graft survival in favor of bladder drain-
age: HR, 3.81 (P = 0.051).
Donor Quality and Graft Survival
Median PDRI was 1.24. Quality of donors decreased since
the start of the transplant program, indicated by an increase
of median PDRI. The PDRI was calculated for each period:
1984 to 1991: PDRI, 1.14 (0.68–2.20); 1992 to 1998: PDRI,
1.20 (0.73–2.01); 1999 to 2005: PDRI, 1.25 (0.72–2.31);
2006 to 2012: PDRI, 1.39 (0.70–2.21). The PDRI of 5 recip-
ients could not be calculated. The PDRI was not associated
with pancreas graft survival in univariate analysis, when
analyzed as a continuous variable (P = 0.25). However, PRDI
1.24 or higher donor grafts had significant poorer out-
come compared to PDRI less than 1.24: 71.2% versus 83.8%
graft survival at 5 years follow-up (P = 0.007). Starting in
2011, so far, 6 recipients were transplanted using grafts from
donation after circulatory determination of death (DCDD)
donors.14With these numbers, DCDD did not influence graft
survival (P = 0.86).
DISCUSSION
This article is an overview of 30 years of pancreas trans-
plantation at our center.
Results, measured in patient and pancreas graft survival
as defined by the OPTN, have improved over the last decade.
As shown in this study, survival, especially 1-year graft
survival, has significantly improved since the introduction
of modern regimes of pre-transplantation induction therapy.
Improvement in surgical technique and maintenance immu-
nosuppression therapy, however, may also have contributed
to improved outcome. Furthermore, clinical experience with
pancreas transplantation has improved throughout the
center over the course of these 30 years. Incidence of kidney
biopsy-proven acute rejection has also declined with intro-
duction of modern induction therapy.
Several limitations apply to the study. It concerns single-
center results, albeit from one of the larger pancreas trans-
plantation centers in Europe. Because of the retrospective
nature of our study, some selected data are incomplete.
Because routine follow-up in our center does not include
measurement of plasma c-peptide, values were only used
for the determination of graft failure when present.
We have shown satisfying results in concordance with
other large transplant centers and databases: Ollinger et al10
report a 94.3% patient survival and 81.5% pancreas graft
survival (exogenous insulin dependent) at 5-year follow up
in the last decade in Innsbruck, Austria. The largest series
of pancreas transplantations described is from Minnesota
and reports 1-year patient survival rates between 93.8%
and 96.2% and 1-year death censored pancreas graft
survival between 78.6% and 80.7% for local or imported
allografts between 1998 and 2008 (P > 0.05).6 Vinkers re-
ported 1-year graft survival of 82% for recipients of P-PASS
less than 17 donor allografts and 64% for recipients of
P-PASS of 17 or higher donor allografts in a Eurotransplant
cohort. Muthusamy et al15compared DBD donors to DCDD
donors in the United Kingdom and reported 88% versus
87% (P = 0.9) 1-year pancreas graft survival, defined as
insulin administration dependency.
Discussion still remains about the value of predictive models.
We have shown that median PDRI is not associated with
pancreas graft survival in this series. The authors believe
TABLE 3.
Multivariate analysisa of risk factors influencing pancreas
graft survival
Factor HR 95% CI P
Donor kidney side
Left kidney ref.
Right kidney 3.18 1.49‐6.76 0.003
No kidneyb n/a n/a
Transplant type
SPK ref.
PTA/PAK 3.68 1.65‐8.19 0.001
Procurement center
Local ref.
Nonlocal 2.72 1.11‐6.68 0.029
Pancreas cold ischemia time 0.90 0.81‐0.99 0.033
Recipient cerebrovascular disease
No ref.
Yes 3.52 1.41‐8.78 0.007
a Forward selection stepwise multivariate analysis using OPTN definition for graft survival.
b Unable to calculate HR due to stratum effect.
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that the increase of PDRI over time, together with simul-
taneous increase of pancreas graft survival over time, is re-
sponsible for this absent relationship. The continuous
increase in PDRI over the years has not led to inferior out-
come. On the contrary, outcome is still improving, whereas,
from 2006 till 2012, median donor PDRI was 1.39, equally
to an United Network for Organ Sharing donation after
cardiac determination of death donor.8 In 2012, Leiden Uni-
versity Medical Center was the second largest whole organ
pancreas transplantation center in the Eurotransplant re-
gion.16 Combining both findings might implicate that high-
volume transplant centers might be able to compensate for
inferior donor quality and that, currently, PDRI might not
yet be reliable enough to predict outcome in the European
cohort. As we have shown earlier, liver donor quality, mea-
sured in DRI, is inferior in the European region, as com-
pared to the United States.17 Additional studies from own
center show a relationship between pancreas graft survival
and PDRI, when using median PDRI (1.24) as a cutoff value
in multivariate analysis (unpublished data).
Multivariate analyses revealed left or right donor kidney,
transplant type, local origin of procurement center, pancreas
cold ischemia time, and recipient cerebrovascular disease as
individual determents of OPTN-defined death-censored
pancreas graft survival. Interestingly, primary bladder drain-
age was borderline favorable for graft survival after multi-
variate analysis, even with nonconverted patients, which
have inferior outcome, included in this group. This result
is similar to results found by Finger et al7 when composing
a risk model for predicting TF. The authors feel that the
2-step approach, initial bladder drainage followed by con-
version to enteric drainage, is a suitable and feasible drainage
method for high-risk recipients, for example, with repeated
peritonitis or high-risk donors or grafts.18,19 However, risks
of repeated surgery will have to be measured against graft
survival benefit, as was stated earlier by Sollinger et al5 who
reported no difference in outcome for both techniques. Even
though the use of UW as perfusion fluid was a protective
factor in univariate analysis, this effect did not remain sig-
nificant after multivariate analysis. It has previously been
shown that the use of histidine-tryptophan-ketoglutarate
bears an increased risk of graft failure in pancreas trans-
plantation.20 The lack of relationship in this series might be
due to the large amount of transplantations that were con-
ducted using UW solution as perfusate. The use of DCDD
pancreas did not influence graft survival in this series, and
is, as we have shown earlier, a feasible option to expand
the donor pool.14 After multivariate analysis, donor cardiac
arrest was no longer a protective factor for pancreas graft
survival. Also, donor cardiac arrest did not influence kidney
graft survival. The authors believe that, in this study, the
effect could be explained by small sample size, even
though reports are published where ischemic precondi-
tioning might have a beneficial effect on outcome.21 Pan-
creas graft thrombosis is still an important complication
after pancreas transplantation, even with modern regimes
of anticoagulation therapy.
All pancreas transplantations (SPK, PTA, and PAK) were
analyzed together. It was previously shown that pooled re-
sults provide useful data for reporting on program-specific
outcome.22 Results might even be better in patient and graft
survivals if only SPK transplantations were analyzed because
it is known that both other categories are associated with
poorer outcome.10
In our opinion, preemptive SPK transplantation is a fea-
sible option in recipients suffering from preterminal renal
disease. This is indicated by the high number of preemptive
transplantations that was carried out at our center. Even
though it did not influence graft survival, preventing recipi-
ents from becoming dialysis-dependent, provides improved
quality of life in the pretransplantation phase. Interestingly,
next to studies demonstrating superior outcome in kidney
graft survival, depending on donation of left or right
kidney,23 this study demonstrates that a donated left or
right kidney significantly influences pancreas graft survival.
This could be explained, however, by the large difference in
1-year kidney graft survival of left and right donated kidneys.
Early kidney graft loss results in a pancreas-alone state, prob-
ably with comparable results as initial PTA transplantations.
Right renal vein length and possible fragility might bear an
increased thrombosis risk; however, in this study, this does
not appear to be the reason for inferior kidney graft survival
of the right kidney. The authors do not have an explanation
for high rejection rates with donated right kidneys.
Pancreas graft survival in this study was death censored
and measured using the OPTN PTC definition as guideline,
where death with functioning graft was not considered graft
failure. Using this definition allows for objective measure-
ment of graft failure, using HbA1c, fasting plasma glucose,
and casual plasma glucose, rather than measuring graft fail-
ure using restart of insulin therapy definition, for this, is, in
our opinion, a more subjective way and also, predominantly,
physician dependent.
When using the restart of any exogenous insulin after the
directly postoperative period as a measure for pancreas graft
survival or graft failure, results are different. Insulin-defined
graft survival is different than OPTN-defined graft survival,
with a difference of almost 6% at 10 year follow-up. Com-
paring both definitions of graft survival and (re)initiating,
the discussion on the definition of graft survival will be sub-
ject of further studies. Without a general consensus on the
definition of graft survival, future studies comparing graft
survival in different cohorts would be difficult. Future
studies will also have to be evaluated for their definitions
of pancreas graft survival.
Even though center size was not investigated in this study
per se, this study still shows that in a large center, a good re-
sult can be achieved without the use of perfect donor grafts.
It is our opinion that future studies will have to point out
the value of center size on the outcome after transplantation,
not only in the field of pancreas transplantation. This opin-
ion was recently shared by Nijboer et al.24 Also, this study
has shown better result with grafts procured by the local
team. This might be because our center performs pancreas
transplantation itself, and this may lead to higher quality of
the transplanted graft and thus improved graft survival.25
In this perspective, the authors believe that early graft failure
should be included in graft survival analysis, especially in
pancreas transplantation because surgical complications are
still an important risk factor in pancreas transplantation.
In conclusion, long-term patient and pancreas graft sur-
vival in this cohort was excellent and at least equal to results
in other large centers. However, the exact nature and inter-
pretation of the findings are highly dependent on which
6 Transplantation ■ Month 2015 ■ Volume 00 ■ Number 00 www.transplantjournal.com
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definition for pancreas graft success or failure is used. Higher
volume transplant centers might be able to achieve the same
outcome in graft survival with higher-risk donors.
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